Cortria Corporation
Cardiovascular Drug Development Company
Website
cortria.com/
Contact Name
Mr. Daniel Grau
Company Position
Chief Executive Officer & Vice-Chairman
Contact Email
info@cortria.com
Contact Address
Old City Hall
45 School Street
Boston MA 02108
USA
Contact Phone
+1 617 456 2008
Cortria is a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease.
The Company is focused on the development and commercialization of TRIA-662 as a new drug candidate for the treatment of dyslipidemia. Unique therapeutic properties of TRIA-662 were first discovered and patented by scientists at the Technical University of Lodz and the patents subsequently acquired by Pharmena, a European pharmaceutical company. Cortria and Pharmena own the dominant intellectual property estate covering pharmaceutical compositions as well as monotherapy and combination uses of 1-methylnicotinamide, the active ingredient in TRIA-662. The companies have signed an exclusive cross-license agreement to this intellectual property estate and Cortria is leading the clinical and commercial development of TRIA-662. Pharmena also has minority shareholder interest in Cortria. Cortria Corporation is based in Boston, MA.
